Capital Counsel’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $364K | Sell |
727
-69
| -9% | -$33.1K | 0.01% | 45 |
|
|
2026
Q1 | $391K | Sell |
796
-1
| -0.1% | -$543 | 0.02% | 45 |
|
|
2025
Q4 | $462K | Hold |
797
| – | – | 0.02% | 42 |
|
|
2025
Q3 | $387K | Sell |
797
-7
| -0.9% | -$3.26K | 0.01% | 46 |
|
|
2025
Q2 | $326K | Sell |
804
-323
| -29% | -$135K | 0.01% | 42 |
|
|
2025
Q1 | $561K | Sell |
1,127
-50
| -4% | -$27.1K | 0.02% | 36 |
|
|
2024
Q4 | $612K | Hold |
1,177
| – | – | 0.03% | 34 |
|
|
2024
Q3 | $728K | Hold |
1,177
| – | – | 0.03% | 33 |
|
|
2024
Q2 | $651K | Sell |
1,177
-16
| -1% | -$9.17K | 0.03% | 35 |
|
|
2024
Q1 | $693K | Buy |
1,193
+445
| +59% | +$250K | 0.03% | 34 |
|
|
2023
Q4 | $397K | Sell |
748
-55
| -7% | -$26.6K | 0.02% | 39 |
|
|
2023
Q3 | $406K | Buy |
803
+5
| +0.6% | +$2.66K | 0.02% | 37 |
|
|
2023
Q2 | $416K | Sell |
798
-32
| -4% | -$17.3K | 0.02% | 37 |
|
|
2023
Q1 | $478K | Hold |
830
| – | – | 0.03% | 36 |
|
|
2022
Q4 | $457K | Sell |
830
-20
| -2% | -$10.6K | 0.03% | 35 |
|
|
2022
Q3 | $431K | Sell |
850
-15
| -2% | -$8.39K | 0.03% | 38 |
|
|
2022
Q2 | $470K | Hold |
865
| – | – | 0.03% | 38 |
|
|
2022
Q1 | $511K | Sell |
865
-146
| -14% | -$83.9K | 0.02% | 41 |
|
|
2021
Q4 | $675K | Sell |
1,011
-56
| -5% | -$35K | 0.03% | 37 |
|
|
2021
Q3 | $610K | Hold |
1,067
| – | – | 0.03% | 38 |
|
|
2021
Q2 | $538K | Hold |
1,067
| – | – | 0.03% | 41 |
|
|
2021
Q1 | $487K | Hold |
1,067
| – | – | 0.03% | 45 |
|
|
2020
Q4 | $497K | Hold |
1,067
| – | – | 0.03% | 43 |
|
|
2020
Q3 | $471K | Hold |
1,067
| – | – | 0.03% | 42 |
|
|
2020
Q2 | $387K | Hold |
1,067
| – | – | 0.03% | 45 |
|
|
2020
Q1 | $303K | Hold |
1,067
| – | – | 0.02% | 48 |
|
|
2019
Q4 | $347K | Buy |
1,067
+32
| +3% | +$9.7K | 0.02% | 50 |
|
|
2019
Q3 | $301K | Hold |
1,035
| – | – | 0.02% | 50 |
|
|
2019
Q2 | $304K | Hold |
1,035
| – | – | 0.02% | 50 |
|
|
2019
Q1 | $283K | Hold |
1,035
| – | – | 0.02% | 52 |
|
|
2018
Q4 | $232K | Hold |
1,035
| – | – | 0.02% | 54 |
|
|
2018
Q3 | $253K | Hold |
1,035
| – | – | 0.02% | 58 |
|
|
2018
Q2 | $214K | Buy |
+1,035
| New | +$220K | 0.02% | 56 |
|
Other funds holding TMO
Capital Counsel's TMO Position: Q2 2026 in Review
Capital Counsel reduced its Thermo Fisher Scientific (TMO) stake by 8.7% in Q2 2026, selling an estimated $33.1K and leaving 727 shares worth $364K. The position accounts for 0.01% of the portfolio, ranked #45.
Capital Counsel first reported a position in TMO in Q2 2018 and has held it in 33 quarters since. The position peaked at $728K in Q3 2024. 2,623 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Capital Counsel held 727 shares of Thermo Fisher Scientific worth $364K as of Q2 2026.
- Capital Counsel sold 69 Thermo Fisher Scientific shares in Q2 2026, an estimated $33.1K.
- Thermo Fisher Scientific made up 0.01% of Capital Counsel's portfolio in Q2 2026, its #45 holding.
- Capital Counsel first reported a position in Thermo Fisher Scientific in Q2 2018 and has held it in 33 quarters since.
- Capital Counsel's Thermo Fisher Scientific position peaked at $728K in Q3 2024.
- 2,623 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Capital Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.